Last 12 months
Inside the activity.
13 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 13 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2021 Filed Mar 16, 2021 16:47 UTC |
Mayer TimothyChief Operating Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001123292-21-000495 · edgar.xml · derivative · entry 1 Mayer Timothy · CIK 0001775460 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-03-14 F1 · derivative.exercise_date: One fourth of the option vests on March 15, 2022. The remainder vests in 36 monthly installments beginning on April 15, 2022. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 16:48 UTC |
Richman MichaelDirector · President & CEO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001123292-21-000496 · edgar.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-03-14 F1 · derivative.exercise_date: One fourth of the option vests on March 15, 2022. The remainder vests in 36 monthly installments beginning on April 15, 2022. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:46 UTC |
Liu LindaSVP, Research
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001123292-21-000494 · edgar.xml · derivative · entry 1 Liu Linda · CIK 0001775427 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-03-14 F1 · derivative.exercise_date: One fourth of the option vests on March 15, 2022. The remainder vests in 36 monthly installments beginning on April 15, 2022. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:45 UTC |
Langermann SolChief Scientific Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001123292-21-000493 · edgar.xml · derivative · entry 1 Langermann Sol · CIK 0001775459 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-03-14 F1 · derivative.exercise_date: One fourth of the option vests on March 15, 2022. The remainder vests in 36 monthly installments beginning on April 15, 2022. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:44 UTC |
Cobourn Steven P.Chief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001123292-21-000492 · edgar.xml · derivative · entry 1 Cobourn Steven P. · CIK 0001775457 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-03-14 F1 · derivative.exercise_date: One fourth of the option vests on March 15, 2022. The remainder vests in 36 monthly installments beginning on April 15, 2022. Read SEC document |
| January 13, 2021 Filed Jan 19, 2021 22:21 UTC |
Myint HanChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $12.09 | $0.00 |
DisclosureSEC source: 0001123292-21-000085 · edgar.xml · derivative · entry 1 Myint Han · CIK 0001840942 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-01-12 F1 · derivative.exercise_date: One fourth of the option vests on January 11, 2022. The remainder vests in 36 monthly installments beginning on February 11, 2022. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 22:26 UTC |
Houston John GDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,687 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001123292-20-001087 · edgar.xml · derivative · entry 2 Houston John G · CIK 0001753537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,687 Underlying: Common Stock · 10,687 shares Expires 2030-09-09 F2 · derivative.exercise_date: The option vests on the earlier of June 11, 2021 and immediately prior to the 2021 Annual Meeting of Stockholders. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 22:26 UTC |
Houston John GDirector
|
GrantStock Option (Right to Buy) · Derivative | 28,500 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001123292-20-001087 · edgar.xml · derivative · entry 1 Houston John G · CIK 0001753537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2030-09-09 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on September 10, 2021. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 20:51 UTC |
Heller Kevin N.Chief Medical Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 27,229 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001123292-20-000983 · edgar.xml · derivative · entry 2 Heller Kevin N. · CIK 0001775716 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,119 Underlying: Common Stock · 27,229 shares Expires 2028-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One fourth of the option vested on April 2, 2019. The remainder vests in 36 monthly installments beginning on May 2, 2019. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 20:51 UTC |
Heller Kevin N.Chief Medical Officer
|
Exercise / conversionCommon Stock | 27,229 | $1.77 | $48,195.33 |
DisclosureSEC source: 0001123292-20-000983 · edgar.xml · nonDerivative · entry 1 Heller Kevin N. · CIK 0001775716 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:36 UTC |
KABAKOFF DAVID SDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $24.13 | $0.00 |
DisclosureSEC source: 0001123292-20-000879 · edgar.xml · derivative · entry 1 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:46 UTC |
Webster Stephen WDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $24.13 | $0.00 |
DisclosureSEC source: 0001123292-20-000884 · edgar.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:37 UTC |
Jones Elaine VDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $24.13 | $0.00 |
DisclosureSEC source: 0001123292-20-000880 · edgar.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 17:42 UTC |
Khuong Chau QuangDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $24.13 | $0.00 |
DisclosureSEC source: 0001123292-20-000881 · edgar.xml · derivative · entry 1 Khuong Chau Quang · CIK 0001609405 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:35 UTC |
Nicholson Garry ADirector
|
GrantStock Option (Right to Buy) · Derivative | 28,500 | $0.00 Strike: $24.13 | $0.00 |
DisclosureSEC source: 0001123292-20-000878 · edgar.xml · derivative · entry 2 Nicholson Garry A · CIK 0001640861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2030-06-10 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 11, 2021. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:35 UTC |
Nicholson Garry ADirector
|
GrantStock Option (Right to Buy) · Derivative | 16,083 | $0.00 Strike: $24.13 | $0.00 |
DisclosureSEC source: 0001123292-20-000878 · edgar.xml · derivative · entry 1 Nicholson Garry A · CIK 0001640861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,083 Underlying: Common Stock · 16,083 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:45 UTC |
Morrison BriggsDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $24.13 | $0.00 |
DisclosureSEC source: 0001123292-20-000883 · edgar.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:47 UTC |
Xu StellaDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $24.13 | $0.00 |
DisclosureSEC source: 0001123292-20-000885 · edgar.xml · derivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:43 UTC |
Li JudithDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $24.13 | $0.00 |
DisclosureSEC source: 0001123292-20-000882 · edgar.xml · derivative · entry 1 Li Judith · CIK 0001754286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 16:35 UTC |
Mayer TimothyChief Operating Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 78,200 | $0.00 Strike: $41.76 | $0.00 |
DisclosureSEC source: 0001123292-20-000458 · edgar.xml · derivative · entry 1 Mayer Timothy · CIK 0001775460 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,200 Underlying: Common Stock · 78,200 shares Expires 2030-02-27 F1 · derivative.exercise_date: One fourth of the option vests on February 28, 2021. The remainder vests in 36 monthly installments beginning on March 28, 2021. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 16:35 UTC |
Richman MichaelDirector · President & CEO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $41.76 | $0.00 |
DisclosureSEC source: 0001123292-20-000457 · edgar.xml · derivative · entry 1 Richman Michael · CIK 0001366265 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: One fourth of the option vests on February 28, 2021. The remainder vests in 36 monthly installments beginning on March 28, 2021. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:38 UTC |
Bingham James B.Chief Development Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 78,200 | $0.00 Strike: $41.76 | $0.00 |
DisclosureSEC source: 0001123292-20-000463 · edgar.xml · derivative · entry 1 Bingham James B. · CIK 0001775735 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,200 Underlying: Common Stock · 78,200 shares Expires 2030-02-27 F1 · derivative.exercise_date: One fourth of the option vests on February 28, 2021. The remainder vests in 36 monthly installments beginning on March 28, 2021. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:37 UTC |
Cobourn Steven P.Chief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 78,200 | $0.00 Strike: $41.76 | $0.00 |
DisclosureSEC source: 0001123292-20-000462 · edgar.xml · derivative · entry 1 Cobourn Steven P. · CIK 0001775457 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,200 Underlying: Common Stock · 78,200 shares Expires 2030-02-27 F1 · derivative.exercise_date: One fourth of the option vests on February 28, 2021. The remainder vests in 36 monthly installments beginning on March 28, 2021. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:37 UTC |
Heller Kevin N.Chief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 100,050 | $0.00 Strike: $41.76 | $0.00 |
DisclosureSEC source: 0001123292-20-000461 · edgar.xml · derivative · entry 1 Heller Kevin N. · CIK 0001775716 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,050 Underlying: Common Stock · 100,050 shares Expires 2030-02-27 F1 · derivative.exercise_date: One fourth of the option vests on February 28, 2021. The remainder vests in 36 monthly installments beginning on March 28, 2021. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:36 UTC |
Langermann SolChief Scientific Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 78,200 | $0.00 Strike: $41.76 | $0.00 |
DisclosureSEC source: 0001123292-20-000460 · edgar.xml · derivative · entry 1 Langermann Sol · CIK 0001775459 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,200 Underlying: Common Stock · 78,200 shares Expires 2030-02-27 F1 · derivative.exercise_date: One fourth of the option vests on February 28, 2021. The remainder vests in 36 monthly installments beginning on March 28, 2021. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:36 UTC |
Liu LindaSVP, Research
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 39,100 | $0.00 Strike: $41.76 | $0.00 |
DisclosureSEC source: 0001123292-20-000459 · edgar.xml · derivative · entry 1 Liu Linda · CIK 0001775427 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,100 Underlying: Common Stock · 39,100 shares Expires 2030-02-27 F1 · derivative.exercise_date: One fourth of the option vests on February 28, 2021. The remainder vests in 36 monthly installments beginning on March 28, 2021. Read SEC document |
| November 27, 2019 Filed Feb 21, 2020 21:11 UTC |
Liu LindaSVP, Research
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,745 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001123292-20-000301 · edgar.xml · derivative · entry 4 Liu Linda · CIK 0001775427 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,373 Underlying: Common Stock · 20,745 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One fourth of the option vested on March 15, 2018. The remainder vests in 36 monthly installments beginning on April 15, 2018. Read SEC document |
| November 27, 2019 Filed Feb 21, 2020 21:11 UTC |
Liu LindaSVP, Research
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 34,489 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001123292-20-000301 · edgar.xml · derivative · entry 3 Liu Linda · CIK 0001775427 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,076 Underlying: Common Stock · 34,489 shares Expires 2026-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One fourth of the option vested on September 1, 2017. The remainder vests in 36 monthly installments beginning on October 1, 2017. Read SEC document |
| November 27, 2019 Filed Feb 21, 2020 21:11 UTC |
Liu LindaSVP, Research
|
Exercise / conversionCommon Stock | 20,745 | $1.21 | $25,101.45 |
DisclosureSEC source: 0001123292-20-000301 · edgar.xml · nonDerivative · entry 2 Liu Linda · CIK 0001775427 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2019 Filed Feb 21, 2020 21:11 UTC |
Liu LindaSVP, Research
|
Exercise / conversionCommon Stock | 34,489 | $0.48 | $16,554.72 |
DisclosureSEC source: 0001123292-20-000301 · edgar.xml · nonDerivative · entry 1 Liu Linda · CIK 0001775427 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:47 UTC |
Sofinnova Venture Partners IX, L.P.10% owner
Sofinnova Management IX, L.L.C.10% owner
HEALY JAMES10% owner
Mehra Anand10% owner
POWELL MICHAEL10% owner
|
PurchaseCommon Stock | 150,000 | $36.75 | $5,512,500.00 |
DisclosureSEC source: 0001104659-19-065582 · tm1923401-1_4.xml · nonDerivative · entry 1 Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner HEALY JAMES · CIK 0001245624 · 10% owner Mehra Anand · CIK 0001590102 · 10% owner POWELL MICHAEL · CIK 0001202793 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,671,856 F1 · ownership.direct: The shares are held directly by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 00:23 UTC |
KABAKOFF DAVID SDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000892 · edgar.xml · derivative · entry 1 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 13, 2020. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 00:20 UTC |
Webster Stephen WDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000887 · edgar.xml · derivative · entry 1 Webster Stephen W · CIK 0001438421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 13, 2020. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 00:23 UTC |
Jones Elaine VDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000893 · edgar.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 13, 2020. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:21 UTC |
SHANNON TIMOTHY MDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000888 · edgar.xml · derivative · entry 1 SHANNON TIMOTHY M · CIK 0001207114 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 13, 2020. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:22 UTC |
Khuong Chau QuangDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000891 · edgar.xml · derivative · entry 1 Khuong Chau Quang · CIK 0001609405 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 13, 2020. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 00:21 UTC |
Morrison BriggsDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000889 · edgar.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 13, 2020. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 00:22 UTC |
Li JudithDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000890 · edgar.xml · derivative · entry 1 Li Judith · CIK 0001754286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 13, 2020. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 00:20 UTC |
Xu StellaDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000886 · edgar.xml · derivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 13, 2020. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:32 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
|
ConversionSeries B-1 Preferred Stock · Derivative | 3,554,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000748 · edgar.xml · derivative · entry 9 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 442,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. F3 · ownership.nature: This report on Form 4 is jointly filed by GP VI and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently Chau Q. Khuong ("Khuong"), an employee of OrbiMed advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Khuong is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or any other purpose. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:32 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
|
ConversionSeries A-3 Preferred Stock · Derivative | 5,861,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000748 · edgar.xml · derivative · entry 8 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 729,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. F3 · ownership.nature: This report on Form 4 is jointly filed by GP VI and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently Chau Q. Khuong ("Khuong"), an employee of OrbiMed advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Khuong is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or any other purpose. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:32 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
|
ConversionSeries A-2 Preferred Stock · Derivative | 5,970,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000748 · edgar.xml · derivative · entry 7 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 743,110 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. F3 · ownership.nature: This report on Form 4 is jointly filed by GP VI and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently Chau Q. Khuong ("Khuong"), an employee of OrbiMed advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Khuong is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or any other purpose. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:32 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
|
ConversionSeries A-1 Preferred Stock · Derivative | 3,582,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000748 · edgar.xml · derivative · entry 6 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 445,866 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. F3 · ownership.nature: This report on Form 4 is jointly filed by GP VI and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently Chau Q. Khuong ("Khuong"), an employee of OrbiMed advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Khuong is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or any other purpose. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:32 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
|
PurchaseCommon Stock | 350,000 | $15.00 | $5,250,000.00 |
DisclosureSEC source: 0001123292-19-000748 · edgar.xml · nonDerivative · entry 5 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments VI, LP Disclosed balance after: 2,711,013 F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:32 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
|
ConversionCommon Stock | 442,438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000748 · edgar.xml · nonDerivative · entry 4 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments VI, LP Disclosed balance after: 2,361,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:32 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
|
ConversionCommon Stock | 729,599 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000748 · edgar.xml · nonDerivative · entry 3 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments VI, LP Disclosed balance after: 1,918,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:32 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
|
ConversionCommon Stock | 743,110 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000748 · edgar.xml · nonDerivative · entry 2 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments VI, LP Disclosed balance after: 1,188,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:32 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
|
ConversionCommon Stock | 445,866 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000748 · edgar.xml · nonDerivative · entry 1 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments VI, LP Disclosed balance after: 445,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Read SEC document |
| May 13, 2019 Filed May 13, 2019 19:32 UTC |
CANAAN X L.P.10% owner
Canaan Partners X LLC10% owner
|
ConversionSeries B-1 Preferred Stock · Derivative | 2,296,605 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000749 · edgar.xml · derivative · entry 9 CANAAN X L.P. · CIK 0001619859 · 10% owner Canaan Partners X LLC · CIK 0001673228 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 285,867 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.direct: The shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| May 13, 2019 Filed May 13, 2019 19:32 UTC |
CANAAN X L.P.10% owner
Canaan Partners X LLC10% owner
|
ConversionSeries A-3 Preferred Stock · Derivative | 5,861,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000749 · edgar.xml · derivative · entry 8 CANAAN X L.P. · CIK 0001619859 · 10% owner Canaan Partners X LLC · CIK 0001673228 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 729,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.direct: The shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.